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Abstract
The objective of this study was to determine the 
empirical efficacy of imidacloprid 10 %/flumethrin 
4.5 % (Seresto®) collars in preventing long-term 
transmission of Ehrlichia canis by infected Rhipi-
cephalus sanguineus ticks to dogs. The study was 
a parallel group design, single centre, randomised, 
non-blinded, controlled, long-term efficacy study. 
The treatment group of 8 dogs was fitted with 
Seresto® collars, the untreated control group of 
8 dogs received no collars. Ehrlichia canis-infected 
ticks were released into the dogs sleeping quarters 
at 14-day intervals up to Day +378. Control group 
dogs infected with E. canis were continuously 
replaced to keep the control sample size constant, 
and a total of 39 control dogs were required. The 
final clinical examination and blood sampling 
occurred on Day +420. The primary assessment 
criterion was the number of dogs infected with 
E. canis, as confirmed by IFA and PCR, and the sec-
ondary criterion was the acaricidal efficacy based 
on tick counts. All scheduled blood samples taken 
were subject to analyses for both PCR and IFA, 
but only positive cases are discussed. Up to Day 
+378, none of the collar-treated dogs were infected 
with E. canis, whereas 34 of the 35 untreated dogs 
enrolled before Day +371 were infected. The acari-
cidal efficacy of the collar ranged from 90 % to 100 % 




Ticks are common ectoparasites present in many 
areas of the world. Rhipicephalus sanguineus is 
the most common tick species in subtropical and 
tropical regions as well as being one of the main 
European tick species (Otranto et al. 2008; Stan-
neck et al. 2012). R. sanguineus is responsible for 
the transmission of Ehrlichia canis to dogs, which 
causes canine monocytic ehrlichiosis (CME), the 
most well-known globally occurring canine tick-
borne disease (Otranto et al. 2008). Dogs with CME 
present a wide range of clinical symptoms, includ-
ing weight loss, lethargy, anorexia, pyrexia, lym-
phadenomegaly and splenomegaly (Harrus et al. 
1997). Occular signs such as corneal opacity may 
also occur and subretinal haemorrhages can lead 
to blindness (Harrus et al. 1998).
The imidacloprid 10 %/flumethrin 4.5 % collar 
(Seresto®) contains a combination of the acaricide 
flumethrin with the insecticide imidacloprid. Flu-
methrin is a highly potent acaricide, which has 
been registered for animal use since 1986 and has 
been used as an active ingredient in the compan-
ion animal product “Kiltix®” collar (propoxur 10 %/
flumethrin 2.25 %) for over 15 years (Liebisch et al. 
1996). The newer Seresto® collar has been avail-
able commercially since 2012 and the active ingre-
dients have been shown to spread from the collar 
over the entire skin surface of the treated animal 
(Stanneck et al. 2012a).
The imidacloprid 10 %/flumethrin 4.5 % collar has 
been shown to be safe and highly effective in the 
treatment and prevention of tick and flea infesta-
tions in cats and dogs. It has been proven to reduce 
tick counts by at least 90 % in cats and dogs under 
field conditions for a period of at least 7–8 months 
(Stanneck et al. 2012b). Though the time frame of 
E. canis transmission by R. sanguineus ticks was 
not part of this study, it is known from current lit-
erature that rickettsial pathogens can be transmit-
ted from ticks to dogs within a short time frame of 
just 4 hours (Nicholson et al. 2010). It is therefore 
important to determine whether the imidacloprid 
10 %/flumethrin 4.5 % collars act fast enough to pre-
vent R. sanguineus ticks from infecting dogs with 
E. canis. The aim of this study was to empirically 
evaluate the long-term efficacy of the Seresto® col-
lar formulation in preventing the transmission of 
E. canis to dogs by infected R. sanguineus ticks.
Materials and methods
General study design
This study was conducted in South Africa and 
lasted from December 2011 to February 2013; 
the last blood collection and clinical examination 
was on Day +420. The study was a parallel group 
design, single centre, randomised, non-blinded, 
controlled, long-term efficacy study conducted on 
two groups each containing eight dogs. Untreated 
control group dogs diagnosed with CME during 
the study were replaced to ensure that the control 
group po pulation remained constant for the dura-
tion of the experimental phase. The sample size of 
eight dogs per group is compliant with the CVMP 
guideline “Guidelines for the Testing and Evalu-
ation of the Efficacy of Antiparasitic Substances 
for the Treatment and Prevention of Tick and Flea 
Infestations in Dogs and Cats”.
Acclimatisation, ranking, collar administration and 
clinical examinations were performed at the time 
intervals shown in Table 1. Collars were replaced 
at Day 155 to provide a full year of collar protection 
during the study with the second treatment period 
ending after the collars’ registered 8 months maxi-
mum efficacy period. In order not to have the last 
month of collar efficacy in the middle of the study, 
an earlier retreatment after 155 days instead of 
8 months was chosen. The approximate one-year 
study duration was designed to mimic an animal 
under full-year protection in a hyperendemic area 
with tick exposure throughout the whole year, as it 




Healthy male and female beagle dogs over 4 months 
in age, with a body weight of between 8 kg and 25 kg 
and complying with predefined inclusion/exclu-
sion criteria were used. All dogs were dewormed, 
harboured no ticks at the initiation of the study 
and were sero-negative for E. canis prior to the 
acclimatisation period. None of the dogs had been 
treated with a topical or systemic acaricide/insec-
ticide 12 weeks prior to acclimatisation start. Dogs 
were identified by electronic transponders with 
unique alphanumeric codes. The study followed 
a randomised block design and the Day –2 body 
weight of each dog was used for ranking and group 
allocation purposes. The 16 dogs initially included 
were ranked, within gender, in descending order of 
individual body weights. Animal ID’s were used to 
break ties. Within each gender, animals were then 
blocked into replicates of two dogs each. Within 
each replicate, dogs were randomly allocated to 
groups 1 (untreated group) or 2 (treated group).
Dose and administration of the  
investigational veterinary product
The investigational veterinary product (IVP) was 
the imidacloprid 10 %/flumethrin 4.5 % collar which 
was fitted according to label instructions on Days 
0 and +155 to the dogs in group 2.
Dogs in the untreated group were not fitted with 
placebo collars.
Tick infestation and tick counts
A laboratory-bred R. sanguineus tick strain infected 
with E. canis was used for the artificial challenges 
in the kennel environment. Infectivity of ticks was 
confirmed by PCR analysis on a sample of between 
30–40 R. sanguineus ticks taken from each batch 
of ticks to be used for the artificial challenges. 
The infectivity of the ticks used for the challenges 
ranged from approximately 2–17 %. For the first 
tick challenge (on Day +14), 20 ticks were used. 
But this amount resulted in a low tick burden, so 
it was decided to increase the number of ticks to 
50 to improve the tick challenge. Therefore, from 
the second challenge (Day +28) onwards, 50 ticks 
were used. Ticks were released in the sleeping ken-
nels of the dogs and the exact number of ticks used 
during each challenge was recorded. The ticks used 
were adult, unfed, at least one week old and had a 
balanced sex ratio of 1:1 of female and male, respec-
tively. Tick counts were in situ on all days except 
Day +380 when ticks were removed and counted.
The findings of the tick counts were categorised as 
shown in Table 3.









Days –7 to –1 Day –2 Day 0 and +155
Days –7 +28, +42, +56, +70, +84, +98, +112, +126, +140, 
+154, +168, +182, +196, +210, +224, +238, +252,+266, 
+280, +294, +308, +322, +336, +350,+364, +378, +392, 
+406 and +420
Table 2 Time schedule of tick challenges and in situ tick counts
Artificial tick challenges Assessments in situ tick counts
Days +14, +28, +42, +56, +70, +84, +98, +112, +126, +140, 
+161, +168, +182, +196, +210, +224, +238, +252,+266, 
+280, 294, +308, +322, +336, +350, +364 and +378
Days +15, +29, +43, +57, +71, +85, +99, +113, +127, +141, 
+162, +169, +183, +197, +211, +225, +239, +253, +267, 
+281, +295, +309, +323, +337, +351 and +365
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Blood collection for PCR analysis
Blood was collected from treated and control groups 
as shown in Table 4. Blood for PCR analysis was 
collected in EDTA tubes. Blood samples for PCR 
analysis were tested at ClinVet International (Pty) 
Ltd. All blood samples taken during scheduled 
sampling occasions were subject to analysis, but 
only positive cases are discussed. In cases where 
clinical signs associated with ehrlichiosis were 
observed, samples were also taken for PCR and 
platelet counts only. Total genomic DNA was iso-
lated from whole blood samples using a commercial 
genomic DNA isolation kit. Polymerase chain reac-
tion entailed the use of primers specific to a region 
of the E. canis dsb gene. Up to 400 ng DNA extract-
ed from whole blood served as template for PCR 
amplification of the target region. PCR products 
were analysed using agarose gel electrophoresis. 
A PCR product of approximately 500 bp indicated 
the presence of the E. canis dsb target region in 
the sample. Positive, negative, no template, as well 
as internal amplification controls were included in 
each run to validate the reactions.
Serum collection for IFA analysis
At least 7 ml of blood was collected from all dogs 
on days indicated in Table 4. Serum was recovered 
from the plain tubes, divided into primary and 
duplicate aliquots and frozen at < –35 °C until 
assayed for E. canis antibodies using a commercial 
IFA test (IGG IFA, Fuller Laboratory) performed 
according to the manufacturer’s description by 
the Department of Veterinary Tropical Diseases 
(DVTD), Faculty of Veterinary Science, University 
of Pretoria, South Africa. All blood samples taken 
during scheduled sampling occasions were subject 
to analysis, but only positive cases are discussed.
Dog welfare and monitoring of clinical 
signs associated with ehrlichiosis
Body temperatures: Rectal body temperatures 
were recorded for all dogs twice weekly (at least 
2 days apart) starting from Day +28 onwards. Rec-
tal body temperatures for dogs with abnormally 
high values (> 39.4 °C) were additionally measured 
the following day again and if still abnormally high, 
a clinical examination was conducted. Blood was 
also collected for platelet counts from these dogs.
Table 3 Categories of findings from tick counts
Category General findings Attachment status
1 Live Free
2 Live Attached; unengorged*
3 Live Attached; engorged**
4 Killed Free
5 Killed Attached; unengorged*
6 Killed Attached; engorged**
* No filling of the alloscutum evident  ** Obvious or conspicuous filling of the alloscutum evident
Table 4 Time points for blood and serum collection 
Blood collection* Serum collection
Days +28, +42, +56, +70, +84, +98, +112, +126, +140, +154, 
+168, +182, +196, +210, +224, +238, +252, +266, +280, 
+294, +308, +322, +336, +350,+364, +378, +392, +406  
and +420
Prior to study inclusion and Days  
+42, +70, +98, +126, +154, +182, +210, +238, +266, +294, 
+332, +350, +378 and +406
*  Blood was collected from dogs that had not yet been diagnosed and treated for ehrlichiosis and additionally from all 
dogs with a body temperature of > 39.4 °C for two consecutive days
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Platelet counts: Blood for platelet counts was 
collected in EDTA tubes on days indicated in 
Table 4. EDTA blood samples for platelet counts 
were examined at Pathcare Veterinary Laboratory, 
Bloemfontein, South Africa.
Clinical examinations: The study dogs were sub-
jected to a clinical examination on the days specified 
in Table 1. The clinical examination included general 
appearance by body system, respiration rate, heart 
rate and body temperature. Additionally, clinical 
examinations were conducted on all dogs displaying 
clinical signs associated with CME, such as fever, 
depression, anorexia, weight loss, haemorrhages, 
epistaxis and gastrointestinal signs such as diar-
rhoea. Dogs with abnormally high body tempera-
tures (> 39.4 °C) and dogs with CME-associated 
clinical signs as observed during the routine daily 
observations were examined by the veterinarian. 
To prevent fatal ehrlichiosis, dogs with abnormally 
high body temperatures (> 39.4 °C) for at least two 
consecutive days and an abnormally low plate-
let count were rescue-treated with doxycycline if 
judged necessary by the examining veterinarian.
General health observations
All animals were observed daily (from Day –7 to 
+420) for general health conditions and clinical 
signs of adverse reactions to treatment. Dogs dis-
playing any abnormal signs were examined by a 
veterinarian.
Statistical analysis
The primary statistical assessment criterion was 
the number of dogs infected with E. canis in the 
untreated control and the treated group. The sec-
ondary statistical assessment criterion was the aca-
ricidal activity of the collar as shown by the number 
of live ticks collected from the untreated control and 
the treated group on the various count days.
The level of significance of the formal tests was 
set at 5 % and all tests were two-sided. The groups 
were compared using an ANOVA with a treatment 
effect after a logarithmic transformation on the 
tick (count + 1) data. The proportion of animals 
infected in each group was compared. SAS Version 
8 (Release 8.02 TS Level 02M0) was used for all the 
statistical analyses.
Calculation of number of dogs infected 
with Ehrlichia canis
A dog successfully infected with E. canis was 
regarded as one that tested serologically positive 
for E. canis antibodies (IFA essay) and tested 
positive for the presence of E. canis DNA by PCR 
analysis.
Any dog that complied with these two criteria was 
regarded as successfully infected.
The percentage blocking efficacy for the treatment 
group was calculated as follows:
Efficacy (%) = 100 x (Tc – Tt) / Tc
Tc =  Total number of infected dogs in the negative  
control group 1
Tt =  Total number of infected dogs in the treatment 
group 2
Calculation of acaricidal activity of the collar
Efficacy against ticks was calculated for the treat-
ment group at each assessment day according 
to the formula given below. Due to the fact that 
small and even zero tick counts were recorded, it 
was expected that the tick counts would not follow 
a normal distribution. Therefore, it was decided 
that the primary efficacy calculations would be 
based on geometric means rather than arithmetic 
means. The calculations were based on the geomet-
ric means of the tick (count + 1) data. One (1) was 
subsequently subtracted from the result to obtain 
a meaningful value for the geometric mean of each 
treatment group. Efficacy calculations based on 
arithmetic means were, however, also reported.
Percent efficacy against ticks was calculated as 
follows:
Efficacy (%) = 100 x (Gmc – Gmt) / Gmc
Gmc =  Geometric or arithmetic mean number of live  
ticks (categories 1–3, as explained in Table 3) on 
dogs in the negative control group (group 1) at 
a specific time point
Gmt =  Geometric or arithmetic mean number of live ticks 
and dead ticks (categories 1–3 and 6) in the treat-





Ehrlichia canis DNA was detected in four collar-
treated dogs of which an infection could only be con-
firmed in two of these dogs by IFA assay. E. canis 
DNA was detected in 36 out of the 39 untreated con-
trol dogs throughout the study experimental phase.
IFA results
Up to Day +350, no E. canis antibodies were detect-
ed in any of the collar-treated dogs. Sero-conversion 
was, however, observed in three collar-treated dogs 
on Day +378 and in two dogs on Day +406. During 
the course of the experimental phase, 39 untreated 
control dogs were exposed to the environmental 
tick challenge of which only one dog did not sero-
convert by Day +406.
Ehrlichia canis blocking efficacy
Infections with E. canis were confirmed by IFA and 
PCR in 2 collar-treated dogs and 36 untreated dogs 
over the 420 day assessment period. Infection with 
E. canis was, however, only first confirmed in the 
two collar dogs on Day +378. The IVP collar, there-
fore, reduced the risk of infections by 100 % up to 
Day +378 and by 94.4 % up to Day +420.
Tick count results
Low tick burdens were observed on the dogs during 
the in situ tick counts on Day +14, so the number of 
ticks used for subsequent challenges was increased 
from 20 to 50. This change was assessed as having 
no negative impact on the study and improved the 
tick challenges on dogs.
Arithmetic and geometric mean tick counts on the 
various assessment days for the two study groups 
are summarised in Table 5. The arithmetic mean 
tick counts recorded for the negative control group 
ranged from 1.5 to 29.0. The geometric mean tick 
counts recorded for the treatment groups differed 
statistically significantly (p < 0.05) from that of the 
untreated control group (group 1) on all assessment 
days.
Acaricidal activity results
Efficacy values of acaricidal activity (%) based on 
arithmetic and geometric mean tick counts are 
summarised in Table 5. Efficacies based on geo-
metric means were considered primary. The IVP 
collar was highly effective against R. sanguineus 
ticks in a simulated kennel environment with effi-
cacies ranging from 90.0–100 % for the duration of 
the assessment period.
Dog welfare and clinical signs associated 
with ehrlichiosis discussion
Of the control and treated groups totalling 39 and 
8 dogs, respectively, 28 control dogs and two treat-
ed dogs had to be rescue-treated for ehrlichiosis. All 
dogs recovered completely.
Body temperatures
The body temperature ranges recorded during the 
routine measurements (excluding those conducted 
during clinical examinations) for the dogs included 
in the study experimental phase are summarised 
in Table 6. Elevated body temperatures (> 39.4 °C) 
were observed in two collar-treated dogs and 25 of 
the 39 untreated control dogs exposed to the envi-
ronmental tick challenges. Infection with E. canis 
was confirmed in all dogs with elevated body 
temperatures.
Platelet counts
The platelet counts are summarised for all dogs in 
Table 6. Low platelet counts were observed an all 
but two dogs confirmed infected with E. canis.
Clinical examinations
The abnormal clinical signs generally associ-
ated with ehrlichiosis observed during the clini-
cal observation conducted at a minimum every 
two weeks are summarised in Table 7. The most 
common abnormal clinical signs observed were 




Table 5  Tick count results (as arithmetic and geometric means of groups 1 and group 2) and percentage efficacy values 
(as calculated from both arithmetic and geometric means)
Day












15 1.5 1.4 0.0 0.0 100.0 100.0
29 4.6 3.7 0.0 0.0 100.0 100.0
43 5.3 4.9 0.0 0.0 100.0 100.0
57 10.2 9.1 0.0 0.0 100.0 100.0
71 7.0 6.5 0.0 0.0 100.0 100.0
85 9.3 5.8 0.0 0.0 100.0 100.0
99 9.0 7.3 0.0 0.0 100.0 100.0
113 13.4 11.5 0.0 0.0 100.0 100.0
127 15.3 13.7 0.0 0.0 100.0 100.0
141 10.9 9.6 0.0 0.0 100.0 100.0
162 9.0 8.1 0.1 0.1 98.6 98.9
169 15.9 12.6 0.1 0.1 99.2 99.3
183 13.4 11.6 0.1 0.1 99.1 99.2
197 13.6 12.9 0.1 0.1 99.1 99.3
211 8.0 7.1 0.1 0.1 98.4 98.7
225 7.1 5.4 0.3 0.1 96.5 97.3
239 8.9 7.9 0.0 0.0 100.0 100.0
253 11.3 10.8 0.3 0.2 97.8 98.2
267 17.4 16.7 0.8 0.5 95.7 97.1
281 16.8 15.9 0.5 0.2 97.0 98.6
295 14.4 13.1 0.4 0.3 97.4 97.7
309 17.3 16.3 2.1 1.5 87.7 90.9
323 11.3 8.2 0.4 0.3 96.7 96.9
337 21.0 19.9 0.3 0.2 98.8 99.1
351 26.0 23.2 0.0 0.0 100.0 100.0
365 29.0 29.0 1.6 0.6 94.4 98.1
380 17.3 10.6 0.0 0.0 100.0 100.0
General health observations
The signs recorded from dogs during the daily 
general health observations are summarised in 
Table 8. All of the signs were seen in group 1 dogs 
and are associated with ehrlichiosis. Dogs received 
appropriate veterinary care.
Adverse events
No adverse events occurred during the clinical 
examinations and daily health observations which 
were regarded as being related to the administra-









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The study reported here was conducted in the spi-
rit of the VICH GL9 (July 2000) guideline on good 
clinical practice to assure high quality standards. 
The study was controlled and the animals were 
randomised. The control group animals were not 
fitted with placebo collars, so blinding was not pos-
sible, but the possibility of bias was considered to 
be minimal as IFA, PCR and tick counts are objec-
tive standardised procedures.
Table 7  Clinical examination summary (only animals for which abnormal signs were recorded are tabulated)
ID GR
E. canis DNA detected 
by PCR (Day)
Clinical observation Study day(s)
CBD FC0 2 +70, +378,+390, +392 Lymph nodes enlarged/swollen +252
CBF BBA 2 – Lymph nodes enlarged/swollen
+224, +238, 
+280, +406
CD4 621 2 – Superficial lymph nodes enlarged +224
CD3 440 2 – Lymph nodes enlarged/swollen +266
957 4F4 2 +378, +392, +406 Lymph nodes enlarged/swollen +266, +392
CD2 370 2 – Lymph nodes enlarged/swollen
+224, +266, 
+322, +331
CD4 7AE 1 +196, +208, +210 Habitus abnormal; still, dull +210
6DC 659 1 +70, +76 Lymph nodes enlarged/swollen +76
CC1 242 1 +168, +378 Lymph nodes enlarged/swollen +224, +378
E16 D69 1 +154, +196 Lymph nodes enlarged/swollen; habitus abnormal +224
E18 3E8 1 +208, +210 Habitus abnormal; still, dull +210




E9B E23 1 +238, +241 Lymph nodes enlarged/swollen +224, +238
CD0 108 1 +226, +279, +280
Lymph nodes enlarged/swollen +252, +280
Serous nasal discharge +280
DF7 72D 1 – Lymph nodes enlarged/swollen +322
6E1 208 1






+308, +316, +322, 
+364
Lymph nodes enlarged/swollen; dull +322
Lymph nodes enlarged/swollen; tick bite dermatitis +331
Lymph nodes enlarged/swollen +350, +364
E9F F45 1
+350, +358, +364, 
+402
Lymph nodes enlarged/swollen +331
B8C B85 1
+308, +322, +323, 
+336, +350, +364
Lymph nodes enlarged/swollen +322
CBE DE2 1 +350, +356, +364 Lymph nodes enlarged/swollen +364
DF6 BEF 1 +350, +358, +364 Lymph nodes enlarged/swollen +331, +364
ID = Idenification; GR = Group; PCR = Polymerase chain reaction; G = Gender.
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Also the 2 % to 17 % prevalence of E. canis infection 
in the ticks used for the challenges was regarded as 
representative for field situations, as prevalences 
of E. canis in ticks reported from different endemic 
areas (either mammalian hosts or questing adults 
in the environment) vary between 0.09 % and 10 % 
(Aguiar et al. 2007; Satta et al. 2011; Harrus et al. 
2011).
The primary objective was the transmission pre-
vention ability for E. canis and, therefore, the 
number of dogs infected by E. canis. None of the 
Seresto® collar-treated dogs were infected for the 
first year of the study, despite being subjected to 
216 infestation events (= animals x infestation time 
points). Towards the end of the experimental phase 
(Day +378), two collar-treated dogs were infected 
by E. canis as confirmed by PCR and IFA. By con-
trast, dogs in the control group had to be replaced 
frequently due to E. canis infections, necessitating 
a total of 39 dogs for the complete experimental 
phase. Of these 39, 36 became infected as con-
firmed by IFA and PCR.
The secondary objective was the acaricidal effi-
cacy based on tick counts. The geometric mean 
tick count for the collar-treated dogs was low and 
ranged from 0.0 (at the first ten time points) to 
1.5 during the entire assessment period. In com-
parison, the geometric mean tick count for untreat-
ed dogs was considerably higher and ranged from 
1.4 (at the first time point when only 20 ticks were 
used to challenge) to 29.0 during the same period. 
Acaricidal efficacies ranged from 90.0 % to 100 % for 
the entire assessment period.
In summary, the empirical efficacy of the Seresto® 
collar in preventing long-term transmission of 
E.canis by infected R. sanguineus ticks to dogs has 
been evaluated for the first time. The collar pre-
vented E. canis transmission by 100 % up to Day 
+378 (197 days after the most recent collar appli-
cation) and by 94.4 % up to Day +420 (223 days 
after the most recent collar application). Acari-
cidal efficacy ranged from 90.0 % to 100 %. These 
results show that the collar is not only effective 
at killing R. sanguineus, but also that the onset of 
acaricidal action is quick enough to prevent ticks 
from transmitting the E. canis infection over a time 
period consistent with the label efficacy period of 
8 months.
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Table 8 General health observation summary
Animal ID Group Day Observation
CC1 315 1 +36 Listless
CC1 315 1 +38 Listless
6DC 659 1 +76 Depresses
6DC 659 1 +77 Listless
436 B01 1 +124 Listless
436 B01 1 +125 Poor appetite
436 B01 1 +126 Listless and poor appetite
9B5 23D 1 +148 Listless
CC1 369 1 +188 Listless (Body temp. 39.6 °C)
E16 D69,  
CDE 2A2
1 +201 Listless, poor appetite
CD4 7AE 1 +208 Poor appetite
CD0 108 1 +278 Listless
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